Abcellera Biologics Inc
ABCL4.170USD
-0.050-1.18%
Cierre 09/08, 16:00（ET）Cotizaciones retrasadas 15 min
1.25BCap. mercado
PérdidaP/E TTM
Más Datos de Abcellera Biologics Inc Compañía
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
Información de la empresa
Símbolo de cotizaciónABCL
Nombre de la empresaAbcellera Biologics Inc
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoDr. Carl L.G. Hansen, Ph.D.
Número de empleados596
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 11
Dirección150 W 4Th Avenue
CiudadVANCOUVER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísCanada
Código postalV5Y 1G6
Teléfono16045599005
Sitio Webhttps://www.abcellera.com/
Símbolo de cotizaciónABCL
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoDr. Carl L.G. Hansen, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Desglose de ingresos
Divisa: USDActualizado: sáb., 22 de feb
Divisa: USDActualizado: sáb., 22 de feb
FY2024Q2
FY2023Q2
Por negocioUSD
Nombre
Ganancia
Proporción
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Otro
60.85%
Accionistas
Accionistas
Proporción
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Otro
60.85%
Tipos de accionistas
Accionistas
Proporción
Corporation
18.79%
Hedge Fund
16.22%
Investment Advisor
15.65%
Individual Investor
4.15%
Investment Advisor/Hedge Fund
2.99%
Bank and Trust
1.20%
Private Equity
1.13%
Research Firm
0.63%
Venture Capital
0.32%
Otro
38.92%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
372
214.57M
71.89%
-123.81K
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
2023Q1
423
223.82M
78.22%
-38.92M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Thermopylae Holdings Ltd
56.14M
18.81%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.22%
--
--
Mar 31, 2025
Capital World Investors
13.36M
4.48%
+5.43M
+68.41%
Mar 31, 2025
Baillie Gifford & Co.
11.20M
3.75%
-1.04M
-8.50%
Mar 31, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
Two Sigma Investments, LP
5.77M
1.93%
-94.12K
-1.60%
Mar 31, 2025
UBS Asset Management (Americas) LLC
6.61M
2.21%
+6.61M
--
Mar 31, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.38%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
9.06M
3.04%
+4.56M
+101.35%
Mar 31, 2025
UBS Switzerland AG
5.05M
1.69%
+4.91M
+3556.81%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
1.77%
TrueShares Technology, AI & Deep Learning ETF
1.53%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
Invesco Nasdaq Biotechnology ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
SPDR S&P International Small Cap ETF
0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción1.77%
TrueShares Technology, AI & Deep Learning ETF
Proporción1.53%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.98%
Invesco Nasdaq Biotechnology ETF
Proporción0.13%
ProShares Ultra Nasdaq Biotechnology
Proporción0.11%
iShares Biotechnology ETF
Proporción0.1%
SPDR S&P International Small Cap ETF
Proporción0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.01%
SPDR Portfolio Developed World ex-US ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
